PREPARATION USEFUL FOR, AND METHOD FOR TREATMENT OF NEONATAL ALLOIMMUNE THROMBOCYTOPENIA (NAIT)
A preparation useful for, and a method for the prophylactic treatment of women post-childbirth in order to avoid immunization and antibody production, which could induce NAIT and fetal/neonatal bleeding in subsequent pregnancies comprising administering a preparation containing antibodies to HPA1a within 72 hours after delivery in the first non-compatible pregnancy.
1 - 17 . (canceled)
18 . A preparation useful in inhibiting an immune response to human platelet antigen HPA 1a, the preparation comprising an Immunoglobulin G (IgG) concentrate containing antibodies specific to human platelet antigen HPA 1a.
19 . The preparation as claimed in claim 18 , wherein the IgG concentrate is derived from human plasma.
20 . The preparation as claimed in claim 18 , wherein the preparation comprises 100-400 μg anti-HPA 1a antibodies.
21 . The preparation as claimed in claim 20 , wherein the preparation comprises 200-300 μg anti-HPA 1a antibodies.
22 . The preparation as claimed in claim 18 , wherein the preparation comprises 50-200 μg/ml anti-HPA 1a antibodies.
23 . The preparation as claimed in claim 18 , wherein the preparation comprises 66-266 μg/ml anti-HPA 1a antibodies.
24 . The preparation as claimed in claim 23 , wherein the preparation comprises 100-150 μg/ml anti-HPA 1a antibodies.
25 . The preparation as claimed in claim 23 , wherein the preparation comprises 133-200 μg/ml anti-HPA 1a antibodies.
26 . The preparation as claimed in claim 18 , wherein the preparation comprises 200-800 μg/ml anti-HPA 1a antibodies.
27 . The preparation as claimed in claim 26 , wherein the preparation comprises 400-600 μg/ml anti-HPA 1a antibodies.
28 . A method for the production of a preparation useful in the prophylactic treatment of NAIT, the method comprising the steps of:
a. Identifying blood plasma donors having HPA 1a antibodies,
b. Collecting plasma from the donors, and
c. Fractionating IgG from the plasma
wherein the fractionated IgG is aliquoted into dosages comprising:
(i) 100-400 μg anti-HPA 1a antibodies, or
(ii) 50-200 μg/ml anti-HPA 1a antibodies, or
(iii) 200-800 μg/ml anti-HPA 1a antibodies.